Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astal LaboratoriesBOM:512600 -2.31%53 Return-on-Tangible-Asset is 11.96% as of Jun. 2026, which is 10773% above its 10-year median of 0.11. GuruFocus rates BOM:512600 with a GF Score™ of 53/100 and a GF Value™ of ₹139.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Astal Laboratories ranks better than 76.07% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Astal Laboratories's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹377 Mil. Astal Laboratories's average total tangible assets for the quarter that ended in Jun. 2026 was ₹3,150 Mil. Therefore, Astal Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 11.96%.
The historical rank and industry rank for Astal Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
BOM:512600'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.53 Med: 0.11 Max: 17.86
Current: 9.67
During the past 13 years, Astal Laboratories's highest Return-on-Tangible-Asset was 17.86%. The lowest was -1.53%. And the median was 0.11%.
BOM:512600's Return-on-Tangible-Asset is ranked better than 76.07% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.89
vs BOM:512600: 9.67
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Astal Laboratories Return-on-Tangible-Asset Related Terms
Astal Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Astal Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:512600 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Astal Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astal Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astal Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Astal Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 11.96% mean?
Astal Laboratories (BOM:512600) has a Return-on-Tangible-Asset of 11.96% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Astal Laboratories and its competitors. This is 10773% above median its historical median of 0.11. According to the industry distribution chart, Astal Laboratories ranks #241 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Astal Laboratories' Return-on-Tangible-Asset too high?
Astal Laboratories' current Return-on-Tangible-Asset of 11.96% is 10773% above median its 10-year median of 0.11. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.89. Astal Laboratories' value of 11.96% is 313.8% above this industry median. Based on the distribution chart, Astal Laboratories ranks #241 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astal Laboratories has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Astal Laboratories' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astal Laboratories ranks #241 out of 1007 companies for Return-on-Tangible-Asset. This places Astal Laboratories in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.89. Astal Laboratories' value of 11.96% is 313.8% above this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 2.89, Astal Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.89, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astal Laboratories's current Return-on-Tangible-Asset of 11.96% is 313.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Astal Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astal Laboratories's current Return-on-Tangible-Asset is 11.96%, which is 10773% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astal Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Astal Laboratories (BOM:512600) is currently considered Possible Value Trap. The stock's GF Value™ is ₹139.73, compared to a current price of ₹78.74 — trading 43.6% below its estimated fair value. The current Return-on-Tangible-Asset is 11.96%, which is 10773% above median its 10-year median of 0.11 and 313.8% above the Drug Manufacturers industry median of 2.89. Astal Laboratories' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Astal Laboratories (BOM:512600), the current Return-on-Tangible-Asset is 11.96% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astal Laboratories (BOM:512600) Overvalued in 2026?
Based on GuruFocus' analysis, Astal Laboratories stock appears to be undervalued.
The current stock price of ₹78.74 is trading 43.6% below its estimated GF Value™ of ₹139.73.
GuruFocus considers Astal Laboratories to be Possible Value Trap.
Key valuation signals for BOM:512600:
Return-on-Tangible-Asset: 11.96% (10773% above median its 10-year median of 0.11)
GF Value™: ₹139.73 vs. price of ₹78.74 (43.6% below fair value)
Industry Position: 313.8% above the Drug Manufacturers median (#241 of 1007)
No single metric tells the full story. See the BOM:512600 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astal Laboratories Ltd is an India-based company. The main objects of the company are to manufacture and sales of Pharmaceutical Intermediates and Bulk Drugs. The company has a single segment, i.e., Pharmaceuticals.
53GF Score
Get the complete analysis for BOM:512600
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512600 has been successfully added to your 
